Tübingen's messenger RNA vaccine and drug developer's latest round includes a $171m investment by strategic partner GlaxoSmithKline.
Sana Biotechnology has closed its first round with more than $700m after investors including GV swung behind its vision to commercialise cell therapies.
Oxford Nanopore is reportedly eyeing a $2.1bn private placement that could offer an exit to Woodford Investment Management.
Existing investor Tencent is in talks as part of a round TUM's flying car developer reportedly aims to close at between $400m and $500m.
FlixMobility has raised a reported $561m in series F funding, adding to earlier capital provided by investors including TUM-linked UVC Partners and carmaker Daimler.
University of Calgary-born Parvus Therapeutics has inked an $800m deal with Genentech to develop and commercialise treatments for autoimmune diseases.
Half a year after raising $500m in a TUS Holdings-backed series B round, the electric car developer is seeking another $500m before it floats.
Telematics system developer and MIT spinout Cambridge Mobile Telematics has raised $500m from Vision Fund that will be used for product development.